CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 431 enrolled
Drug / intervention
1.2% JNJ 10229570-AAA +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01326780
NCT01326780Phase 2Completed
CompareCT.gov

A Multi-Center, Double-Blind, Vehicle Controlled, Phase II Study of JNJ 10229570-AAA for the Treatment of Acne Vulgaris

Bausch Health Americas, Inc.·interventional·Posted Mar 31, 2011·Updated Oct 16, 2019

In Brief

A Phase 2 clinical trial evaluating 1.2% JNJ 10229570-AAA, 2.4% JNJ 10229570-AAA, and 2 other interventions for Acne Vulgaris. Completed, enrolled 431 participants across 18 sites.

Detailed Summary

A study to determine if three different doses of a new acne treatment are safe and better at reducing facial acne than a treatment without active ingredient.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 31, 2011
Enrollment StartMar 31, 2011
Primary CompletionMar 31, 2012
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 15.3 years ago

Interventions

1.2% JNJ 10229570-AAAdrug

1.2% JNJ 10229570-AAA 1.2% cream applied once daily to the face for 12 weeks

2.4% JNJ 10229570-AAAdrug

2.4% JNJ 10229570-AAA 2.4% cream applied once daily to the face for 12 weeks

3.6% JNJ 10229570-AAAdrug

3.6% JNJ 10229570-AAA 3.6% cream applied once daily to the face for 12 weeks

Vehicle controlother

Color matched cream vehicle, applied once daily to the face for 12 weeks